Postmenopausal Osteoporosis Treatment Market Report 2025

The postmenopausal osteoporosis treatment market size has grown steadily in recent years. It will grow from $10.1 billion in 2024 to $10.58 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to aging population, hormone replacement therapy, increased awareness, fracture risk reduction, nutritional supplements.

The postmenopausal osteoporosis treatment market size is expected to see strong growth in the next few years. It will grow to $13.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to healthcare infrastructure growth, increased screening programs, precision medicine approaches, biosimilars in osteoporosis treatment, bone health in women's health programs, digital health integration, regenerative medicine approaches. Major trends in the forecast period include diagnostic advances, new drug development, emerging therapies, collaborations for drug development, integration of ai.

The projected increase in osteoporosis prevalence is expected to drive the growth of the postmenopausal osteoporosis treatment market. Osteoporosis, characterized by reduced bone mass and weakened bone tissue, poses an increased risk of fractures. Postmenopausal osteoporosis treatment plays a crucial role in preventing or managing the condition, reducing fracture risks, and enhancing overall health outcomes. A report from Healthy Bones Australia revealed a rise in fractures related to osteoporosis or osteopenia from 178,439 in 2021 to 183,105 in 2022, emphasizing the need for effective postmenopausal osteoporosis treatments.

The rising prevalence of obesity is expected to drive the growth of the postmenopausal osteoporosis treatment market in the future. Obesity is a medical condition marked by an excessive accumulation of body fat that can negatively affect health. Treatment for postmenopausal osteoporosis is particularly beneficial for individuals with obesity, as it helps increase bone density, reduce fracture risk, strengthen bones, and improve overall bone health by slowing down bone loss. This comprehensive health management can lead to a better quality of life by decreasing the risk of fractures, which significantly impacts mobility and independence. For example, in 2023, the Outdoor Industry Association (OIA), a U.S.-based non-profit, reported a 2.3% increase in outdoor recreation participants in 2022, reaching an all-time high of 168.1 million, which constitutes 55% of the U.S. population aged six and older. Thus, the growing prevalence of obesity is fueling the expansion of the postmenopausal osteoporosis treatment market.

Product innovations are emerging as a significant trend in the postmenopausal osteoporosis treatment market. Major companies in this sector are concentrating on developing innovative products, such as parathyroid hormone, to enhance efficacy and patient adherence. They are also investigating combination therapies and personalized medicine to improve treatment outcomes. Additionally, there is a strong emphasis on long-term safety studies and patient support programs to address concerns and encourage compliance. Parathyroid hormone (PTH) is produced by the parathyroid glands and plays a crucial role in regulating calcium levels in the blood. It promotes calcium release from bones, enhances reabsorption in the kidneys, and activates vitamin D to increase intestinal calcium absorption. For example, in November 2023, Apotex Corp., a pharmaceutical company based in Canada, launched teriparatide, a recombinant parathyroid hormone that significantly boosts bone mineral density and reduces fracture risk in individuals with osteoporosis. Its anabolic effects stimulate bone formation, making it an essential treatment for high-risk patients.

Major companies in the postmenopausal osteoporosis treatment market are striving to gain a competitive edge through innovative products. Advanced bone-building medications, typically administered through injections to promote bone health and density, are a focus of development. In November 2023, Teva Pharmaceuticals Inc., a U.S-based pharmaceutical company, received FDA approval for Forteo (teriparatide injection), catering to postmenopausal women with osteoporosis at high fracture risk. The approval underscores the significance of innovative bone-building medications in treating osteoporosis in both men and women.

Major companies operating in the postmenopausal osteoporosis treatment market include Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Dr.Reddys Laboratories Ltd., Hikma Pharmaceuticals PLC., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Takeda Pharmaceutical Company Limited, Lupin Limited, Ligand Pharmaceuticals Incorporated, Torrent Pharmaceuticals Limited.

North America was the largest region in the postmenopausal osteoporosis treatment market in 2024. The regions covered in the postmenopausal osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the postmenopausal osteoporosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The postmenopausal osteoporosis treatment market consists of revenues earned by entities by providing screening and diagnosis, bone density testing, and risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The postmenopausal osteoporosis treatment market also includes sales of selective estrogen receptor modulators and osteoporosis drugs that are used for the treatment of postmenopausal osteoporosis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Postmenopausal osteoporosis treatment refers to medical interventions and strategies aimed at managing and preventing bone loss and fractures in women after menopause. Postmenopausal osteoporosis is characterized by decreased bone density and an increased susceptibility to fractures due to hormonal changes after menopause.

The main types of drugs used in postmenopausal osteoporosis treatment include bisphosphonates, vitamin D3, estrogen agonists or antagonists, hormone replacement therapy, parathyroid hormone therapy, and others. Bisphosphonates, a class of medications, are commonly used to treat various bone-related conditions, with osteoporosis being a notable example. These medications can be administered through oral, parenteral, and other routes, and they are available through various distribution channels, including hospital pharmacies, retail pharmacies, and others.

The postmenopausal osteoporosis treatment market research report is one of a series of new reports that provides postmenopausal osteoporosis treatment market statistics, including postmenopausal osteoporosis treatment industry global market size, regional shares, competitors with a postmenopausal osteoporosis treatment market share, detailed postmenopausal osteoporosis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the postmenopausal osteoporosis treatment industry. This postmenopausal osteoporosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.